A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 39.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. The RSI reading of 24.25 for SAVA is an indication that the heavy selling could be in the process of exhausting itself, ...

Cassava Sciences (SAVA) recently suffered yet another setback, which raises concern regarding its prospects. Nonetheless, simufilam is being evaluated for the treatment of Tuberous sclerosis complex (TSC)-related epilepsy. The company also has an investigational diagnostic product candidate, SavaDx, in its portfolio. SavaDX is a novel biomarker assay being studied for the detection of Alzheimer's disease from a small blood sample. Last week, the company announced that the phase III study REFOCUS-ALZ on lead ...

Shares of Cassava Sciences (SAVA) plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second late-stage study for Alzheimer’s disease (AD). Simufilam is SAVA’s proprietary, investigational oral small molecule that targets the filamin A protein.Cassava released top-line results from the phase III REFOCUS-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug fa ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s diseaseSimufilam continued to demonstrate an overall favorable safety profileCassava’s Alzheimer’s disease development program with simufilam will be completely discontinued by the end of Q2 2025 AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology com ...

Cassava Sciences, Inc. (SAVA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inve ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 6801 N. Capital of Texas Highway, Building 1; Suite 300, Austin, TX 78731 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

Financial Position - Unaudited cash and cash equivalents balance as of December 31, 2024 was approximately $128.6 million[4] Workforce Reduction - The company reduced its workforce by 10 employees, a reduction of 33%[7] - Estimated one-time costs of approximately $0.4 million related to severance payments for the workforce reduction[8] - Workforce reduction expected to be completed, and associated costs incurred, during the first quarter of 2025[8] Clinical Trials and Study Results - Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet prespecified co-primary endpoints[6] - The company decided to discontinue its Phase 3 ReFocus-ALZ study and its open-label extension study[6] - The company plans to share detailed study results at a future medical meeting[10] Forward-Looking Statements and Risks - Forward-looking statements include risks related to clinical study timelines, unexpected costs, and drug development uncertainties[11] Regulatory and Reporting - The company's press release dated January 7, 2025, is attached as Exhibit 99.1[12] - The report is signed by Eric J. Schoen, Chief Financial Officer, on January 7, 2025[15]

Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic application for simufilam for seizures related to tuberous sclerosis complex (TSC)$128.6 Million in Cash and Cash Equivalents at December 31, 2024 AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused o ...

Core Viewpoint - Cassava Sciences has entered into a licensing agreement with Yale University for intellectual property rights related to simufilam, aimed at treating seizures associated with rare neurodevelopmental disorders, particularly tuberous sclerosis complex (TSC) [1][3]. Group 1: Licensing Agreement - The agreement includes an exclusive license to US method of treatment patent (US 12,186,307) for simufilam [1][8]. - The licensed intellectual property is based on research conducted by Dr. Angélique Bordey and her team at Yale, which demonstrated that simufilam significantly reduced seizure frequency in an animal model [2][3]. Group 2: Research and Development - Cassava plans to conduct preclinical studies in collaboration with the TSC Alliance to further evaluate simufilam's potential as a treatment for TSC-related seizures [3]. - Simufilam is a proprietary investigational oral small molecule that targets the filamin A protein [4][9]. Group 3: Tuberous Sclerosis Complex (TSC) - TSC is a neurodevelopmental disorder caused by mutations in the mTOR pathway genes, leading to seizures in 80% to 90% of patients [5][6]. - Approximately two-thirds of TSC patients do not respond to current antiepileptic drugs, resulting in lifelong seizures and associated disabilities [6]. Group 4: Market Potential - TSC affects an estimated 1 in 6,000 live births, with around 50,000 individuals in the United States and over one million worldwide living with the condition [7].

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline.So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...